# US 2010/0168771 A1 · Systems and methods to affect anatomical structures

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168771 A1
- Document ID: US20100168771A1
- Status: Published application
- Kind: A1
- Application number: 12/625,069
- Filed: 2009-11-24
- Published: 2010-07-01
- Earliest claimed: 2008-11-24
- Assignees: Georgia Tech Research Corporation
- Inventors: ROBERT E. GULDBERG; Yash M. Kolambkar; Dietmar W. Hutmacher
- Web page: https://patentgrep.com/patent/US20100168771A1

## CPC

- A61F 2/2846: {Support means for bone substitute or for bone graft implants, e.g. membranes or plates for covering bone defects (nets or sleeves applied to surface of endoprostheses A61F2/30907; bone plates A61B17/80; bone regeneration in dental surgery A61C8/0006)}
- A61L 27/3804: {characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells}
- A61L 27/3834: {Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells}
- A61L 27/52: Hydrogels or hydrocolloids
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61L 31/146: {Porous materials, e.g. foams or sponges}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61F 2/30767: {Special external or bone-contacting surface, e.g. coating for improving bone ingrowth}
- A61F 2/3094: {Designing or manufacturing processes}
- A61F 2002/0068: {having a special mesh pattern}
- A61F 2002/2817: {Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]}
- A61F 2002/2825: {Femur}
- A61F 2002/285: {Fixation appliances for attaching bone substitute support means to underlying bone}
- A61F 2002/30028: {differing in tissue ingrowth capacity, e.g. made from both ingrowth-promoting and ingrowth-preventing parts}
- A61F 2002/30075: {swellable, e.g. when wetted}
- A61F 2002/30235: {tubular, e.g. sleeves}
- A61F 2002/30838: {Microstructures}
- A61F 2002/3084: {Nanostructures}
- A61F 2002/30914: {Details of the mesh structure, e.g. disposition of the woven warp and weft wires}
- A61F 2002/3092: {having an open-celled or open-pored structure}
- A61F 2210/0061: swellable
- A61F 2230/0069: cylindrical
- A61F 2240/001: Designing or manufacturing processes
- A61F 2310/00365: Proteins; Polypeptides; Degradation products thereof
- A61L 2300/414: Growth factors
- A61L 2400/06: Flowable or injectable implant compositions
- A61L 2400/12: Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
- A61L 2430/02: for reconstruction of bones; weight-bearing implants
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

The various embodiments of the present invention are generally directed to systems and methods to affect anatomical structures. More particularly, the various embodiments of the present invention are directed to systems and methods to regenerate bone. An aspect of the present invention comprises a system for affecting an anatomical structure, comprising: a nanofiber mesh configured to substantially conform to an anatomical structure, wherein at least a portion of the nanofiber mesh defines a fillable space; a carrier substance comprising an active agent, such as a bone morphogenetic protein, wherein the carrier substance is disposed within the fillable space.

## Claims

### Claim 1

A system for affecting an anatomical structure, comprising: a nanofiber mesh configured to substantially conform to an anatomical structure; and an active agent.

### Claim 2 (depends on 1)

The system for affecting an anatomical structure of claim 1, further comprising: a carrier substance.

### Claim 3 (depends on 2)

The system for affecting an anatomical structure of claim 2, wherein at least a portion of the nanofiber mesh defines a fillable space, and wherein the carrier substance is disposed within the fillable space.

### Claim 4 (depends on 3)

The system for affecting an anatomical structure of claim 3, wherein the nanofiber mesh has an average pore size of less than about 100 micrometers.

### Claim 5 (depends on 3)

The system for affecting an anatomical structure of claim 3, wherein the nanofiber mesh further comprises a plurality of macropores.

### Claim 6 (depends on 1)

The system for affecting an anatomical structure of claim 1, wherein the active agent comprises at least one member of the transforming growth factor beta superfamily.

### Claim 7 (depends on 6)

The system for affecting an anatomical structure of claim 6, wherein the carrier substance comprises a hydrogel.

### Claim 8 (depends on 7)

The system for affecting an anatomical structure of claim 7, wherein the anatomical structure is bone, and wherein the carrier substance comprises alginate or a derivative thereof, and wherein the at least one member of the transforming growth factor beta superfamily comprises a bone morphogenetic protein.

### Claim 9 (depends on 8)

The system for affecting an anatomical structure of claim 8, wherein the active agent further comprises a plurality of mesenchymal progenitor cells.

### Claim 10

A method for affecting an anatomical structure, comprising:
adapting a nanofiber mesh to an anatomical structure of a subject so that the nanofiber mesh substantially conforms to the anatomical structure, wherein the at least a portion of the nanofiber mesh defines a fillable space; and
flowing a carrier substance into the fillable space, wherein the carrier substance comprises an active agent, and wherein at least a portion of the carrier substance is disposed within the fillable space.

### Claim 11 (depends on 10)

The method for affecting an anatomical structure of claim 10, wherein the nanofiber mesh has an average pore size of less than about 100 micrometers.

### Claim 12 (depends on 10)

The method for affecting an anatomical structure of claim 10, wherein the carrier substance comprises a hydrogel.

### Claim 13 (depends on 10)

The method for affecting an anatomical structure of claim 10, wherein the active agent comprises at least one member of the transforming growth factor beta superfamily.

### Claim 14 (depends on 13)

The method for affecting an anatomical structure of claim 13, wherein the anatomical structure comprises a bone, and wherein the carrier substance comprises alginate or a derivative thereof, and wherein the at least one member of the transforming growth factor beta superfamily comprises a bone morphogenetic protein.

### Claim 15 (depends on 14)

The method for affecting an anatomical structure of claim 14, further comprising regenerating at least a portion of the bone, wherein the bone morphogenetic protein is present in an initial concentration of less than about 100 micrograms per kilogram of body weight of the subject.

### Claim 16 (depends on 14)

The method for affecting an anatomical structure of claim 14, the active agent further comprising a plurality of mesenchymal progenitor cells.

### Claim 17

A kit for affecting an anatomical structure, comprising:
a membrane configured to substantially conform to an anatomical structure, wherein at least a portion of the membrane can define a fillable space; and
a flowable hydrogel system comprising at least one active agent.

### Claim 18 (depends on 17)

The kit for affecting an anatomical structure of claim 17, wherein the membrane comprises a nanofiber mesh having an average pore size of less than about 100 micrometers.

### Claim 19 (depends on 18)

The kit for affecting an anatomical structure of claim 18, wherein the nanofiber mesh further comprises a plurality of macropores.

### Claim 20 (depends on 18)

The kit for affecting an anatomical structure of claim 18, wherein the anatomical structure is bone, and wherein the flowable hydrogel comprises alginate or a derivative thereof, and wherein the active agent comprises a bone morphogenetic protein.
